Holen Sie sich die Stockscreener-App
634.52
0.70%
-4.3599
Schlusskurs vom Vortag:
$638.88
Offen:
$642.45
24-Stunden-Volumen:
461.15K
Relative Volume:
0.62
Marktkapitalisierung:
$66.56B
Einnahmen:
$14.92B
Nettoeinkommen (Verlust:
$4.42B
KGV:
15.46
EPS:
41.0422
Netto-Cashflow:
$3.79B
1W Leistung:
+0.65%
1M Leistung:
-15.59%
6M Leistung:
-19.15%
1J Leistung:
+7.82%
1-Tages-Spanne:
$634.15
$648.50
1-Wochen-Bereich:
$632.72
$651.00
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
634.88 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
436.52 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
806.13 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.74 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.40 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing - The Motley Fool
U.S. biotech giant Regeneron chooses Hyderabad to set up GCC - The Hindu
Canaccord Cuts PT on Regeneron Pharmaceuticals (REGN), Cites a Disappointing Event - Insider Monkey
Important Notice to Long-Term Shareholders of Molina - GlobeNewswire
US biotech giant Regeneron to set up its first Global Capability Centre outside America in Hyderabad - NewsMeter
Are Wall Street Analysts Predicting Regeneron Pharmaceuticals Stock Will Climb or Sink? - Yahoo Finance
Regeneron Pharmaceuticals to set up Global Capability Centre (GCC) in Hyderabad - Telangana Today
Legal & General Group Plc Sells 27,332 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US biotech major Regeneron identifies site for its GCC to be operational in 2nd half of 2026 in Hyderabad - Pharmabiz.com
Prospera Financial Services Inc Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Jefferies Financial Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US Biotech Regeneron to launch Global Capability Centre in Hyderabad - BioSpectrum India
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Trial Wins And New Research Partnership - simplywall.st
US biotech Regeneron to launch global capability centre in India's Hyderabadstatement - marketscreener.com
Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins - Yahoo! Finance Canada
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN) - marketscreener.com
5 Cheap NASDAQ Stocks to Buy Right Now - Insider Monkey
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Simplify Asset Management Inc. - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN): Analyst Ratings Signal Strong Buy with 30% Upside Potential - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
The week in pharma: action, reaction and insight – week to May 22, 2026 - The Pharma Letter
Why Regeneron (REGN) Is Down 8.5% After Melanoma Trial Miss and New Legal ScrutinyAnd What's Next - simplywall.st
Swedbank AB Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by LSV Asset Management - MarketBeat
Regeneron R&D Updates Test Market View On Long Term Pipeline Value - Yahoo Finance
Stocks making big moves this week: Toll Brothers, Booz Allen Hamilton, Strategy, Regeneron, and Micron - Yahoo Finance
ABN Amro Investment Solutions Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus - simplywall.st
Regeneron (REGN) Advances Gene Therapy Review in Europe - GuruFocus
Licensable picture: The exterior of Regeneron Pharmaceuticals May 22, 2026 in Tarrytown. - Reuters Connect
Parabilis Medicines Starts IPO On Promising Cancer Therapy Trials (PBLS) - Seeking Alpha
Regeneron Says Otarmeni Application Accepted Under EU Accelerated Assessment - Moomoo
EMA accepts Regeneron’s gene therapy for rare hearing loss By Investing.com - Investing.com Canada
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss - The Manila Times
Rx Rundown: Parabilis Medicines, Boston Scientific, Amgen and more - Medical Marketing and Media
REGN News | REGENERON PHARMACEUTICALS (NASDAQ:REGN) - ChartMill
(REGN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc.REGN - PR Newswire
Regeneron reports positive trial results for amyloidosis treatment By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Reports Encouraging LINKER-AL2 Trial Results for Lynozyfic® in Systemic AL Amyloidosis - Quiver Quantitative
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals, Inc. Cash Flow – BVL:REGNUS - TradingView
Jim Cramer on Regeneron: “There Could Be Some More Downgrades” - Insider Monkey
Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN) - GlobeNewswire
Regeneron-backed Parabilis Medicines seeks US IPO - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron backed Parabilis Medicines seeks U.S. IPO - Seeking Alpha
Why Regeneron (REGN) Shares Are Trading Lower Today - Yahoo Finance
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud - Business Wire
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets - Yahoo Finance
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regeneron Pharmaceuticals Inc-Aktie (REGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RYAN ARTHUR F | Director |
Apr 01 '26 |
Sale |
777.27 |
100 |
77,727 |
17,603 |
| RYAN ARTHUR F | Director |
Mar 02 '26 |
Sale |
785.50 |
100 |
78,550 |
17,703 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Option Exercise |
376.69 |
1,638 |
617,018 |
3,341 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Sale |
781.33 |
1,638 |
1,279,812 |
1,703 |
0.92%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):